Difference between revisions of "Plinabulin (NPI-2358)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
m |
||
| (5 intermediate revisions by 2 users not shown) | |||
| Line 1: | Line 1: | ||
| − | =Mechanism of action= | + | ==Mechanism of action== |
From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=488984 NCI Drug Dictionary]: An orally active diketopiperazine derivative with potential antineoplastic activity. Plinabulin selectively binds to the colchicine-binding site of tubulin, thereby interrupting equilibrium of microtubule dynamics; mitotic spindle assembly is disrupted, resulting in cell cycle arrest at the M phase and blockage of cell division in tumor cells. In addition, this agent induces tubulin depolymerization in vascular endothelial cells, resulting in the disruption of tumor blood vessel architecture and a selective collapse of tumor vasculature. | From the [https://www.cancer.gov/publications/dictionaries/cancer-drug?cdrid=488984 NCI Drug Dictionary]: An orally active diketopiperazine derivative with potential antineoplastic activity. Plinabulin selectively binds to the colchicine-binding site of tubulin, thereby interrupting equilibrium of microtubule dynamics; mitotic spindle assembly is disrupted, resulting in cell cycle arrest at the M phase and blockage of cell division in tumor cells. In addition, this agent induces tubulin depolymerization in vascular endothelial cells, resulting in the disruption of tumor blood vessel architecture and a selective collapse of tumor vasculature. | ||
| − | =Preliminary data= | + | ==Preliminary data== |
| − | ==[[Non-small cell lung cancer]]== | + | ===[[Non-small cell lung cancer]]=== |
# '''Abstract:''' Ramon W. Mohanlal, Ken LLoyd, Lan Huang, Lyudmila Bazhenova. Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC. J Clin Oncol 35, 2017 (suppl 7S; abstract 139) [http://meetinglibrary.asco.org/content/178367-194 link to abstract] | # '''Abstract:''' Ramon W. Mohanlal, Ken LLoyd, Lan Huang, Lyudmila Bazhenova. Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC. J Clin Oncol 35, 2017 (suppl 7S; abstract 139) [http://meetinglibrary.asco.org/content/178367-194 link to abstract] | ||
| − | + | ==Also known as== | |
| − | [[Category: | + | *'''Code name:''' NPI-2358 |
| + | |||
| + | [[Category:Drugs]] | ||
| + | |||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
| − | [[Category:Non-small cell lung cancer medications]] | + | [[Category:Non-small cell lung cancer medications (investigational)]] |
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Latest revision as of 02:18, 29 April 2022
Mechanism of action
From the NCI Drug Dictionary: An orally active diketopiperazine derivative with potential antineoplastic activity. Plinabulin selectively binds to the colchicine-binding site of tubulin, thereby interrupting equilibrium of microtubule dynamics; mitotic spindle assembly is disrupted, resulting in cell cycle arrest at the M phase and blockage of cell division in tumor cells. In addition, this agent induces tubulin depolymerization in vascular endothelial cells, resulting in the disruption of tumor blood vessel architecture and a selective collapse of tumor vasculature.
Preliminary data
Non-small cell lung cancer
- Abstract: Ramon W. Mohanlal, Ken LLoyd, Lan Huang, Lyudmila Bazhenova. Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC. J Clin Oncol 35, 2017 (suppl 7S; abstract 139) link to abstract
Also known as
- Code name: NPI-2358